Conclusion: 53 adult patients infected HPVB19 in 10 years at community hospital in Japan. Epidemic season were 4year cycle and skin eruption and joint symptoms appeared 4-5 days after upper respiratory symptoms. Previous study show that a second-phase illness with rash and arthralgia appear 10-11 days after the appearance of upper respiratory symptoms. In our study, a second-phase symptoms appeared about one week earlier than in previous study. Half of the patients were weakly ANA positive.

References:

Season of onset

Clinical symptoms and time course

<table>
<thead>
<tr>
<th>Days</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15</td>
</tr>
<tr>
<td>2</td>
<td>17</td>
</tr>
<tr>
<td>3</td>
<td>30</td>
</tr>
<tr>
<td>4</td>
<td>47</td>
</tr>
<tr>
<td>5</td>
<td>62</td>
</tr>
<tr>
<td>6</td>
<td>71</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.797

FR010445 HLA-B27 IN POSTSTREPTOCOCCAL REACTIVE ARTHRITIS WITH ENTHESIS

I. Naishetik1, L. Khimion1, O. Yashchenko1, P. Dolinskiy2, 1National Medical Academy of Postgraduate Education named after P.L. Shupyk, Kyiv, Ukraine; 2The Institute of Traumatology and Orthopedics, Kyiv, Ukraine

Background: Poststreptococcal reactive arthritis (PSRA) is a very common diagnosis in rheumatology practice, which develops after recent pharyngeal streptococcal infection and characterized by aseptic inflammation in one or more joints and periarticular involvement. Now no diagnostic criteria have been agreed [2,4]; association of the expression of HLA-B27 and PSRA is not clear [1,3].

Objectives: In our study we analyzed the features of PSRA in presence of HLA-B27.

Methods: 88 patients (48 female and 40 male) aged between 18-55 years with complains of pain, tender and swollen joints developed after recent pharyngeal streptococcal infection underwent standard physical and laboratory rheumatological examinations. Acute rheumatic fever and other inflammatory arthritis were excluded.

Results: 60 patients (68.2%) had oligo-polymyalgia, 10 patients (11.4%) monoarthritis, 24 patients (27.3%) had asymmetrical oligoarthritis, 4 patients (4.5%) had polyarthrits, enthesis was found in 4 (4.5%) patients, tenosynovitis of the palmar flexor tendons in 10 cases (11.4%) and the peroneal tendons of the ankles in 5 patients (5.7%), one-sided sacroiliitis (confirmed by MRI) in 5 patients (5.7%). The mean level of ASL-O was 542 U/ml, CRP - 15 mg/L, ESR - 34 mm/H; HLA-B27 was present in 24 (30.7%) patients. HLA-B27 positivity was connected to enthesitis, sacroiliitis, more joint involvement with higher levels of ESR and CRP.

Conclusion: 30% of patients with poststreptococcal reactive arthritis are HLA-B27 positive, the presence of HLA-B27 leads to more frequent development of enthesitis, polyarthritis and sacroiliitis with higher level of inflammatory activity which dictate the need for longer supervision of such patients for possible triggering of ankylosing spondylitis development.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular.2546

FR010446 VIRAL ARTHRITIS: DESCRIPTIVE ANALYSIS OF A SERIES OF 131 PATIENTS

A. V. Orenes Vera1, I. Vázquez-Gómez2, L. Montoloi-Chiva3, E. Flores1, D. Ybañez1, E. Valls-Pascual4, A. Martínez-Ferrer5, A. Sendra-García6, V. Núñez-Monje1, J. J. Alegre-Sancho1, A. V. Orenes Vera1, I. Vázquez-Gómez2, L. Montoloi-Chiva3, E. Flores1, D. Ybañez1, E. Valls-Pascual4, A. Martínez-Ferrer5, A. Sendra-García6.

Background: Arthritis of viral aetiology is considered the most frequent cause of acute arthritis. The most common etiologic agent is parvovirus B19 (B19). Besides, other viruses can lead to inflammatory joint disease, such as Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Human immunodeficiency virus (HIV), Rubella, Mumps, Hepatitis B and C virus (HBV and HCV) and Chikungunya (in transcontinental travellers or immigrants).

Objectives: To describe the epidemiological characteristics, clinical and analytical course, evolution and treatment of a series of patients with a confirmed diagnosis of viral arthritis.

Methods: A descriptive study was performed, considering a series of cases of viral arthritis collected between 2000 and 2019. Epidemiological (sex, age, the season of the year, year of diagnosis, children of pediatric age), clinical (joint pattern, prodromes, accompanying clinic) and analytical (CRP, ESR, ANA, RF) variables were collected. Statistical analysis was performed with the SPSS 22.0 program.

Results: The data of 131 patients (109 women, 22 men), with a mean age of 39.7 years (SD 11.9) were collected. 92.9% of the cases were produced by B19, 3.6% by EBV, and only 3 by other viruses (1 by CMV, 1 by HBV, 1 by Mumps). The highest incidence years were 2005(55 cases), 2000(10 cases) and 2016(8 cases). Almost half of the cases (46.6%) occurred in spring, while 32.8% in summer, 15.3% in winter and 5.3% in autumn. Contrary to the expectations, only 20% of the patients had children in pediatric age.

The most frequent clinical picture was acute polyarthritis (53.4%), followed by inflammatory polyarthralgias (19.1%). Moreover, acute oligoarthritis was present in 10.7% of cases, and acute monoarthritis in 3.1% of cases. More than half of the patients (54.2%) had prodromes, most frequently respiratory symptoms, and the joint clinic was accompanied by a skin rash in 35.1% and fever in 29% of cases. Analytically, 33.6% presented high CRP, 39.7% high ESR, 19.8% transient anemia, 9.9% positive ANA (4.6% transiently), 9.1% anti ds-DNA (7.6% transiently), and 10.7% positive RF (3.1% transiently). In 79.4% of cases, the clinic picture was limited, with a mean duration of 36 days (SD 47.7), but 12.3% had recurrences. The 69.5% of the patients needed treatment with acetylsalicylic acid and/or NSAIDs (6.7% did not need treatment), but corticotherapy was needed in 21.4% of cases. 4.6% of the cases evolved to chronicity, which made DMARD necessary in 3 patients (two of them with a final diagnosis of rheumatoid arthritis, being treated with Methotrexate and Leflunomide, and the third one had a diagnosis of undifferentiated connective disease, treated with Hydroxychloroquine).

Conclusion: B19 remains the most common cause of viral arthritis in our population. It appears with a sporadic, occasionally epidemic, pattern of presentation, predominantly in warm seasons. A clinical presentation as an oligoarthritis or an acute monoarthritis or even the positivity of autoimmunity markers, should not make us rule out this possible aetiology. One out of 20 cases can evolve to chronicity and even make necessary the addition of DMARD.
Disclosure of Interests: Ana V Orenes Vera: None declared, I Vázquez-Gómez: None declared, L Montolio-Chiva: None declared, Eduardo Flores: None declared, Desamparados Ybañez: None declared, Elia Valis-Pascual Grant/research support from: Roche, Novartis, and AbbVie, Speakers bureau: AbbVie, Lilly, Pfizer, MSD, Novartis, Janssen, Bristol Myers Squibb, UCB Pharma, À Martinez-Ferrer: None declared, A Sendra-García: None declared, V Núñez-Monje: None declared, Inmaculada Torner Hernández: None declared, Juano J Alegre-Sancho Consultant of: UCB, Roche, Sanofi, Boehringer, Celltrion, Paid instructor for: GSK, Speakers bureau: MSD, GSK, Lilly, Sanofi, Roche, UCB, Actelion, Pfizer, Abbvie, Novartis, Nagore Fernandez-Llanio: None declared

DOI: 10.1136/annrheumdis-2020-eular.5390

FIRST COMPREHENSIVE LONG-TERM ASSESSMENT OF MUSCULOSKELETAL CONSEQUENCES AMONG EBOLA SURVIVORS

V. M. Perez1, A. Dubois2, T. A. Barry3, M. D. Sal5, L. March4, M. S. Sow2, A. K. Keita1, B. Taverner5, J. F. Etard4, A. Toure5, M. Barry5, E. Delaporte6 on behalf of Postebogui Study Group. 1CHU Montpellier, Montpellier, France; 2Rheumatology Department, CHU Brive, France; 3Donka University National Hospital, Conakry, Guinea; 4LPEID UMR 151, Aix Marseille Univ, IRD, LPEID, Marseille, France; 5TransVHMI INSERM, IRD, University of Montpellier, Montpellier, France; 6Conakry University, Conakry, Guinea; 7University Gamal Nasser, Conakry, Guinea

Background: The tremendous size of the 2013-2016 West African outbreak of Ebola virus disease (EVD) resulted in a sizeable population of survivors, many reporting short-term sequelae such as arthralgia and myalgia.

Objectives: We aimed to report a detailed and long-term description of patients’ musculoskeletal (MS) symptoms.

Methods: We performed a cross-sectional study following systematic rheumatological screening of patients included in the Postebogui cohort (Conakry district). We used regression models to establish the magnitude of EVD as a risk factor for developing chronic MS pain by comparison with a control cohort and to establish risk factors for developing MS pain among survivors.

Results: The study included 313 patients (55.6% female), with a median age of 28.2 years (IQI 21-37), and a median time from ETC discharge to rheumatological visit of 26.2 months (IQR 23-30). Chronic MS pain was reported in 216 (69%) patients, and was predominantly mechanical (48%). Enthesis and painful peripheral joints were largely involved (91%) with symmetrical distribution. Previous Ebola infection was a major risk factor for chronic MS pain (aOR, 6.662 [95% CI, 4.522–9.921]). Among survivors, increasing age (OR 1.14, 95% CI 1.08–1.21) and previous Ebola infection were both associated with persistent MS pain, while myalgia experienced during the acute phase of EVD appeared protective (OR 0.14, 95% CI 0.04–0.42).

Conclusion: Our study provides the most accurate long-term description of MS disorders among Ebola survivors. Joint and muscle pain sequelae are frequent and require specialized care.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1216

FOUR CASES OF SYPHILIS MIMICKING RHEUMATOLOGICAL CONDITIONS PRESENTING TO THE GENERAL RHEUMATOLOGY SERVICE AT ST GEORGES HOSPITAL, LONDON, UK IN 2018-2019

S. Qureshi1, K. Moss1, A. Ezeonyejii, V. Sandhu1. 1St George’s Hospital, London, United Kingdom

Background: Sir William Osler once wrote: “He, who knows syphilis, knows medicine.”

Whilst the Tuskegee Syphilis trials live in infamy, the advent of successful penicillin treatment and sexual health education resulted in the lowest recorded incidence ever in 2001.

Unfortunately, cases of syphilis have nearly tripled in the past decade (from 2,847 in 2009 to 7,541 in 2018 in the UK). WHO now estimates the global median prevalence of Syphilis, among men who have sex with men, is 6%.

The current cohort of clinicians will therefore have limited clinical experience of Syphilis, which can often mimic rheumatic conditions. We present the clinical experience of a tertiary teaching centre hospital.

Objectives: To identify the scope of clinical cases, with a diagnosis of Syphilis, during 2018-2019 at St Georges University Hospital, London, UK.

Methods: Clinical cases were identified by health professionals and a retrospective review of medical records was undertaken.

Results: There were 4 cases identified during 2018-19.

Case 1: The patient was diagnosed with bilateral uveitis secondary to primary syphilis, and immunosuppression may have contributed to this.

Case 2: The rash developed after the initial presentation and an extended infection screen was performed.

Case 3: The patient had a 6 month duration of symptoms and had had a negative sexual health screen 1 year prior to presentation.

Case 4: The patient had no features of extra pulmonary sarcoidosis and an infectious screen was undertaken.

All 4 cases were referred to the Infectious Disease Unit for treatment. 3 patients received standard treatment with Penicillin, and 1 patient received an oral course of Doxycycline, due to a penicillin allergy.

2 of the 4 cases had complete resolution of symptoms, and 2 of the cases had only partial resolution of symptoms at the time of publication.

Conclusion: Syphilis can present with an inflammatory arthritis, PMR and GCA–type symptoms, ocular inflammation, neurological disturbance and rashes that can mimic autoimmune conditions.

Our cases highlight the increasing incidence, as well as the risk of reactivation following immunosuppressive current practice does not advise routine testing for syphilis prior to initiation of immunosuppressive therapy. However the rising incidence should prompt careful evaluation, and detailed sexual history, particularly in high risk groups. The diagnostic test interpretation and treatment requires close collaboration with Infectious Diseases Specialists.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.1270

MANAGEMENT AND OUTCOME OF SEPTIC ARTHRITIS OF NATIVE JOINT: A NATIONWIDE SURVEY

P. Riche1, S. Godorf2, G. Coffier3, P. Guggenbuhl4, D. Mulleran, M. Couderc5, E. Demia6, V. Deprez7, C. Salloir7, S. Uren7, R. Brailli6, A. Ruyssen-Witrand7, E. Hoppe7, J. E. Gottenberg13, C. Roux7, S. Ottaviani15, M. Breban2, M. Beaufra6, A. Michault17, L. Pauveile18, C. Darrieutort19, D. Wendling20, P. Coquerelle21, G. Bart22, E. Gervais23, V. Goeb24, M. Ardzzone25, E. Pertuiset26, S. Delo27, J. M. Zizza28, R. M. Filipo29, R. Seror on behalf of Osteoarticular Infection Study Group. 1Strasbourg University Hospital, Le Kremlin-Bicêtre, France; 2University Hospital of Dijon, France; 3Dijon University Hospital, France; 4Reims University Hospital, France; 5Pitié-Salpêtrière Hospital, Paris, France; 6Lille University Hospital, Lille, France; 7University Hospital of Lille, France; 8University Hospital of Nice, Nice, France; 9Rouen University Hospital, Rouen, France; 10Bicêtre University Hospital, Paris, France; 11Toulouse University Hospital, Toulouse, France; 12Angers University Hospital, Angers, France; 13Strasbourg University Hospital, Strasbourg, France; 14Nice University Hospital, Nice, France; 15Besançon University Hospital, Besançon, France; 16Chu Montpellier, Montpellier, France; 17Paris University Hospital, Paris, France; 18Clermont-Ferrand University Hospital, Clermont-Ferrand, France; 19Lyon University Hospital, Lyon, France; 20Montpellier University Hospital, Montpellier, France; 21Besançon University Hospital, Besançon, France; 22Bicêtre University Hospital, Paris, France; 23Amiens University Hospital, Amiens, France; 24Orléans University Hospital, Orléans, France; 25Cochin University Hospital, Paris, France; 26Poitiers University Hospital, Poitiers, France; 27Toulouse University Hospital, Toulouse, France; 28Bordeaux University Hospital, Bordeaux, France; 29Amiens University Hospital, Amiens, France; 30Besançon University Hospital, Besançon, France; 31Lyon University Hospital, Lyon, France; 32Besançon University Hospital, Besançon, France

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5390

Downloaded from http://ard.bmj.com/ on September 18, 2023 by guest. Protected by copyright.